Related Experiment Video
Updated: Aug 7, 2026

Generation of Fluorescent Protein Fusions in Candida Species
Published on: March 4, 2017
Ceftazidime in neonatal infections
Insights
Ceftazidime showed high serum concentrations and good cerebrospinal fluid penetration in neonates. However, it was ineffective against Gram-positive organisms, limiting its use as monotherapy before culture results are known.
Area of Science:
- Neonatal pharmacology
- Infectious diseases
- Antibiotic therapy
Background:
- Neonatal infections require effective and safe antibiotic treatment.
- Ceftazidime is a broad-spectrum cephalosporin with theoretical suitability for neonatal use.
- Limited data exist on ceftazidime efficacy and safety in neonates.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous ceftazidime in neonates with suspected or proven infections.
- To assess ceftazidime serum concentrations, cerebrospinal fluid penetration, and clinical outcomes.
Main Methods:
- A prospective study of 91 neonates receiving 108 courses of intravenous ceftazidime (25 mg/kg, 12-hourly).
- Clinical and bacteriological data were collected for 14 neonates with proven infections.
- Serum drug concentrations and cerebrospinal fluid penetration were monitored.
Main Results:
- High serum ceftazidime concentrations were achieved, exceeding minimum inhibitory concentrations for common pathogens.
- Excellent cerebrospinal fluid penetration was observed in 8 of 9 cases.
- Four neonates with Gram-positive infections (Group B Streptococcus, Staphylococcus aureus) failed to respond.
- Nine neonates showed clinical improvement or bacteriological eradication, with no observed side effects.
Conclusions:
- Ceftazidime demonstrates favorable pharmacokinetic properties in neonates, including high serum levels and CSF penetration.
- The antibiotic was effective against Gram-negative infections but ineffective against Gram-positive organisms in this study.
- Ceftazidime cannot be recommended as monotherapy for neonatal infections until bacteriological culture results are available.
Abstract:
Ninety one neonates received 108 courses of intravenous ceftazidime (25 mg/kg, 12 hourly) over a study period of 15 months. Fourteen had clinically and bacteriologically proved infections. Only one of these had resistant organisms. Four (two with group B beta haemolytic streptococcal infections, one with Escherichia coli meningitis, and one with Staphylococcal aureus septicaemia) failed to respond despite adequate treatment. Bacteriological eradication or clinical improvement, or both, were obtained in the remaining nine. Routine biochemical and haematological values were monitored and there were no side effects. High serum ceftazidime concentrations, well exceeding the minimum inhibitory concentration for most common neonatal pathogens were obtained and maintained throughout treatment. Penetration into the cerebrospinal fluid was excellent in eight of the nine cases studied. Ceftazidime has a theoretical role as a broad spectrum antibiotic suitable for neonatal use with no evident side effects. In this study, however, it was only appropriate for Gram negative infections, and was ineffective against Gram positive organisms. Ceftazidime cannot therefore be recommended as monotherapy before the results of bacteriological culture are known.
Related Concept Videos
Drug Dosing: Infants and Children
Development of the Oral Microbiota
Rocky Mountain Spotted Fever
Mechanism of Antibiotic Resistance in MRSA
Respiratory Syncytial Virus Disease
Inhibitors of Bacterial DNA Synthesis

